STROMA
Stromal Cell- Immune Cell Interactions in Health and Disease
| Coordinatore |
Organization address
address: HESLINGTON contact info |
| Nazionalità Coordinatore | Non specificata |
| Totale costo | 4˙296˙181 € |
| EC contributo | 42 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-01-01 - 2015-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITY OF YORK
Organization address
address: HESLINGTON contact info |
UK (YORK NORTH YORKSHIRE) | coordinator | 1˙139˙401.40 |
| 2 |
UNIVERSITE DE RENNES I
Organization address
address: RUE DU THABOR 2 contact info |
FR (RENNES CEDEX) | participant | 521˙503.72 |
| 3 |
KANTONSSPITAL ST. GALLEN
Organization address
address: Rorschacherstrasse 95 contact info |
CH (ST. GALLEN) | participant | 504˙936.70 |
| 4 |
UNIVERSITEIT TWENTE
Organization address
address: DRIENERLOLAAN 5 contact info |
NL (ENSCHEDE) | participant | 472˙183.56 |
| 5 |
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Organization address
address: Rue Michel -Ange 3 contact info |
FR (PARIS) | participant | 262˙345.62 |
| 6 |
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address
address: 's Gravendijkwal 230 contact info |
NL (ROTTERDAM) | participant | 252˙083.73 |
| 7 |
Institute of Science and Technology Austria
Organization address
address: Am Campus 1 contact info |
AT (Klosterneuburg) | participant | 248˙295.30 |
| 8 |
MEDIMMUNE LIMITED*
Organization address
address: The Milstein Building Granta Park contact info |
UK (Cambridge) | participant | 236˙638.61 |
| 9 |
PROBIOGEN AG
Organization address
address: Goethestrasse 54 contact info |
DE (Berlin) | participant | 234˙876.39 |
| 10 |
INSTITUTO DE MEDICINA MOLECULAR
Organization address
address: AVENIDA PROF EGAS MONIZ contact info |
PT (LISBOA) | participant | 220˙204.56 |
| 11 |
MILTENYI BIOTEC GMBH
Organization address
address: FRIEDRICH EBERT STRASSE 68 contact info |
DE (BERGISCH GLADBACH) | participant | 203˙712.31 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'STROMA is an Initial Training Network promoting the study of stromal cell – immune system interactions during stroma development and function in health and disease. In STROMA we have bought together world leading experts from academia and industry in Europe to address the key scientific questions in this emerging field. STROMA will promote the training of three Experienced Researchers (ER) and seventeen Early Stage Researchers (ESR) combining research and training in state-of-the-art multidisciplinary technologies. Through “hands on” and a “Virtual Learning Environment” STROMA will train the ESRs in the latest imaging, animal models, genomics, infectious biology and stromal biology technologies in collaboration with our industrial partners. STROMA will provide training in communications skills, ethics, plagiarism, grant writing, intellectual property rights, industrial skills training, project management, entrepreneurship, research policy, commercial exploitation of results and public engagement and develop a Personal Training Plan for each ESR and ER. Through network meetings and localized training the ESRs will receive additional training in complementary skills. STROMA is a highly interconnected network with each ER/ESR project involving multiple collaborations and secondments with other network participants including an extensive placement with our industrial partners. The importance of stromal cells and the molecular mechanism of stromal cell function in the regulation of immune responses have only recently been appreciated and are an exciting new area in immunology. The purpose of STROMA is to ensure that Europe retains global leadership in this emerging field and translates basic research on stroma-immune cell interactions to novel products and technologies for European industry.'